These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37548458)

  • 1. Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia.
    Nishida M; Horio T; Fukuda Y; Hayakawa Y; Tateishi Y; Akai M; Emoto M; Hasegawa T; Imanishi M
    Int J Clin Pharmacol Ther; 2023 Oct; 61(10):437-444. PubMed ID: 37548458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
    Iwasaki M; Suzuki H; Umezawa Y; Koshida T; Saito M; Fukuda H; Takahara H; Matsuzaki K; Suzuki Y
    Medicine (Baltimore); 2023 Feb; 102(7):e32818. PubMed ID: 36800602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.
    Nakamura A; Kagaya Y; Saito H; Kanazawa M; Sato K; Miura M; Kondo M; Endo H
    J Atheroscler Thromb; 2023 May; 30(5):443-454. PubMed ID: 35768226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease.
    Tamai H; Okamura J
    Hepatol Res; 2023 Mar; 53(3):258-266. PubMed ID: 36378065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis.
    Dohmen K; Onohara SY; Harada S
    Korean J Gastroenterol; 2021 Oct; 78(4):227-234. PubMed ID: 34697277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Pemafibrate on Serum Creatinine in Patients with Chronic Kidney Disease.
    Imai E; Imai A
    JMA J; 2022 Jul; 5(3):328-333. PubMed ID: 35992291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
    Kito K; Nomoto H; Sakuma I; Nakamura A; Cho KY; Kameda H; Miya A; Omori K; Yanagiya S; Handa T; Taneda S; Takeuchi J; Nagai S; Yamashita K; Kurihara Y; Atsumi T; Miyoshi H;
    Diabetes Res Clin Pract; 2022 Oct; 192():110091. PubMed ID: 36174777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease.
    Izumihara R; Nomoto H; Kito K; Yamauchi Y; Omori K; Shibayama Y; Yanagiya S; Miya A; Kameda H; Cho KY; Nagai S; Sakuma I; Nakamura A; Atsumi T
    Diabetes Metab J; 2024 May; 48(3):473-481. PubMed ID: 38419467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.
    Yanai H; Katsuyama H; Hakoshima M
    Cardiol Res; 2021 Dec; 12(6):358-362. PubMed ID: 34970366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
    Horinouchi Y; Murashima Y; Yamada Y; Yoshioka S; Fukushima K; Kure T; Sasaki N; Imanishi M; Fujino H; Tsuchiya K; Shinomiya K; Ikeda Y
    Life Sci; 2023 May; 321():121590. PubMed ID: 36940907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
    Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
    Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study.
    Shima H; Tashiro M; Inoue T; Okada K; Okamoto T; Wariishi S; Doi T; Minakuchi J
    Cureus; 2024 Apr; 16(4):e57777. PubMed ID: 38715994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
    Katakura Y; Shimoda M; Ohnishi M; Kusano T; Dan K; Isobe H; Wamata R; Iwamoto Y; Fushimi Y; Sanada J; Obata A; Kimura T; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1444-1452. PubMed ID: 37246074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.
    Jonkers IJ; Smelt AH; Princen HM; Kuipers F; Romijn JA; Boverhof R; Masclee AA; Stellaard F
    J Nutr; 2006 Apr; 136(4):987-91. PubMed ID: 16549462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
    Tanaka A; Nakamura T; Sato E; Chihara A; Node K
    CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.
    Yamashita S; Rizzo M; Su TC; Masuda D
    Metabolites; 2023 May; 13(5):. PubMed ID: 37233667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y; Shapiro MD
    Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
    Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
    J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
    Matsuba I; Matsuba R; Ishibashi S; Yamashita S; Arai H; Yokote K; Suganami H; Araki E
    J Diabetes Investig; 2018 Nov; 9(6):1323-1332. PubMed ID: 29603684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.